What is Insulin Aspart?

A rapid-acting mealtime insulin analog; brands include NovoLog, NovoRapid and Fiasp.

Insulin Aspart in the library · · Human Trials · What are peptides?

488 registered trials · 450 indexed papers · 513 human / 0 animal studies

From the PeptideWhiz library entry. "As described" sections summarize claims made in the sources; they are not PeptideWhiz endorsements.

What it is

A rapid-acting mealtime insulin analog; brands include NovoLog, NovoRapid and Fiasp.

Type: Rapid-acting insulin analog.

Definition (National Library of Medicine)

“Insulin that has been modified to contain an aspartic acid instead of a proline at position 38 of the B-chain.”

  • MeSH: Insulin Aspart

Human research

The registered human trials and peer-reviewed human studies linked below are listed from ClinicalTrials.gov and PubMed. A study is linked only when Insulin Aspart is one of its interventions, or is named in the study title or subject headings.

Listing a study does not mean it showed a benefit, and it is not medical advice.

Registered human trials (488)

TrialPhaseStatusYearEnrolled
Comparison of the Pharmacokinetic (PK) and Pharmacodynamic (PD) Biosimilarity of Insulin Aspart 30 Injections After Single-Dose Subcutaneous Administration to Healthy Volunteersnot yet recruiting202652
Comparison of the Pharmacokinetics （PK）and Pharmacodynamics （PD）Biosimilarity of Insulin Aspart Injections After Single-Dose Subcutaneous Administration to Healthy Volunteerscompleted202644
Comparison of the Pharmacokinetics (PK) and Pharmacodynamics (PD) Biosimilarity of Proposed Biosimilar/Interchangeable Rapid-Acting Insulin Aspart (I004) and NovoLog® After Single-Dose Subcutaneous Administration to Healthy VolunteersPhase 2/Phase 3completed202662
CGM-guided Patch Pump vs Basal-Bolus Injection for Steroid-Induced Hyperglycemia in Sudden Sensorineural Hearing Loss: SHIP Trialnot yet recruiting202650
Evaluate the Efficacy and Safety of GZR101-80 Injection in Patients With Type 2 DiabetesPhase 2not yet recruiting2026345
Regimen Transition After Short-Term Intensive Insulin Therapy in Type 2 DiabetesPhase 4not yet recruiting2026324
A Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine, Both in Combination With Insulin Aspart, in Adults With Type 1 DiabetesPhase 3active not recruiting2025877
A Study to Test How Insulin NNC0471-0119 H Works in the Body in Participants With Type 1 Diabetes When Given by an Insulin PumpPhase 1completed202543
Testing a Conversion Factor for a More Rapidly Acting Insulin in an Automated Insulin Delivery System Among Adolescents With T1Dcompleted202511
A Study to Test How Insulin NNC0471-0119 H Works in the Body in Participants With Type 2 Diabetes When Given by an Insulin PumpPhase 1completed202565
Role of ET-1, Physical Activity, and Sedentary Behavior in Microvascular Dysfunction Following GDMEARLY_Phase 1recruiting202440
Study to Demonstrate Pharmacokinetic and Pharmacodynamic Similarity Between NKF-INS(A), US-NovoLog®, and EU-NovoRapid®Phase 1completed202454
A Trial Comparing Efficacy, Tolerability, and Safety of GZR101 Injection Once Daily (OD) and GZR33-70 Injection ODPhase 2unknown202460
A Trial of Three- and Seven-days Insulin Infusions Setrecruiting202480
Comparison of HR011408 and NovoRapid® in Subjects With DiabeticsPhase 1unknown202430
Oxidative Stress in Microvascular Dysfunction Following Gestational DiabetesEARLY_Phase 1recruiting202328
Role of NADPH Oxidase in Microvascular Dysfunction Following GDMEARLY_Phase 1active not recruiting202340
A Study of Insulin Degludec/Insulin Aspart Biosimilar (22011) Compared With Insulin Degludec/Insulin Aspart(Ryzodeg) in Participants With Type 2 Diabetes in ChinaPhase 3completed2023414
Safety and Efficacy of Insulin Degludec/Insulin Aspart in Patients With T2DMcompleted2023218
A Trial Comparing Efficacy and Safety of GZR101 and IDegAsp in Insulin Naïve or Insulin Treated Subjects with T2DMPhase 2completed2023153
AT278, NovoRapid® and Humulin® R (U500) in Glucose Clamp StudyPhase 1completed202341
The Pharmacokinetics and Pharmacodynamics Between HR011408 and NovoRapid® in Healthy SubjectPhase 1completed202361
The Effect of Short-term Insulin Intensive Therapy Based on the Application of Insulin Pump and Real-time Dynamic Glucose Monitoring Technology on Reversing the Newly Diagnosed Type 2 DiabetesPhase 4unknown2023210
Bioequivalence Study of INS062 and Pharmacokinetics and Pharmacokinetics Study of Single Injection of HR20014 in Healthy SubjectsPhase 1unknown202360
Comparison of the Pharmacokinetics (PK) and Pharmacodynamics (PD) Biosimilarity of Proposed Biosimilar Rapid-Acting Insulin Aspart (I004) and NovoLog After Single-Dose Subcutaneous Administration to Healthy VolunteersPhase 2/Phase 3completed202269
A Fully-closed Loop, Pramlintide and Insulin, Artificial Pancreas Clinical Trial for Adults With Type 1 Diabetescompleted202212
Risk of Hypoglycemia in the Transition From Inpatient to Outpatient Setting. Comparative Study of Basal-bolus Insulin Versus Basal Insulin Plus GLP-1 AnaloguePhase 3unknown202266
Research on Optimal Strategy of Hypoglycemic Therapy for Cirrhosis With DiabetesPhase 3unknown2022184
AT247, NovoLog® and Fiasp® Administered Via Continuous Subcutaneous Infusion in Glucose Clamp StudyPhase 1completed202224
Pilot Study Evaluating Safety of ExOlin® in Patients With Poorly Controlled Type 1 Diabetesrecruiting20228
An Indian Post Marketing Study of Mealtime Insulin, Fiasp®, to Evaluate Its Safety and Effectiveness in Patients With Diabetes Mellitus in Routine Clinical Practicecompleted202142
A Research Study Looking at How the Use of NovoPen® 6 for Treatment With Tresiba® & Fiasp® Affects the Blood Sugar Level in Patients With Type 1 Diabetes as Part of Local Clinical Practicecompleted2021411
A Research Study to Compare a New Weekly Insulin, Insulin Icodec, and an Available Daily Insulin, Insulin Degludec, Both in Combination With Mealtime Insulin in People With Type 1 Diabetes (ONWARDS 6)Phase 3completed2021582
A Research Study to Compare Two Types of Insulin, a New Weekly Insulin, Insulin Icodec and an Available Daily Insulin, Insulin Glargine, Both in Combination With Mealtime Insulin, in People With Type 2 Diabetes Who Use Daily Insulin and Mealtime Insulin (ONWARDS 4)Phase 3completed2021582
A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Insulin Glargine Taken Daily With Insulin Aspart (COMBINE 3)Phase 3completed2021679
Afrezza® INHALE-1 Study in PediatricsPhase 3completed2021319
Transition From Basal/Bolus to Once-weekly Subcutaneous Semaglutide and Basal Insulin in Patients With T2DPhase 4completed202160
FASter Insulin in Closed-loop Technology in Childrencompleted202127
Investigating the Effect of Ryzodeg® in Adult Patients With Type 2 Diabetes in Lebanoncompleted202160
Insulin for Hyperglycemia in Stroke TrialPhase 4completed2021452

Peer-reviewed studies (450)

PaperAuthorsJournalYearType
A New Highly Concentrated Insulin Aspart AT278 (500 U/mL) Demonstrates Ultra-Rapid Pharmacokinetic and Pharmacodynamic Properties in Type 2 Diabetes Regardless of BMISvehlikova E et al.Diabetes, obesity & metabolism2026Randomized Controlled Trial
Efficacy and Safety of iGlarLixi Versus IDegAsp by Baseline Age, Disease Duration and HbA1c in Chinese People With Type 2 Diabetes: Post Hoc Analyses of the Soli-D StudyZhang S et al.Diabetes, obesity & metabolism2026Randomized Controlled Trial
Comparative analysis of IDegLira versus insulin glargine in short-term intensive therapy for overweight or obese patients with type 2 diabetes mellitusSun Y et al.Endocrine2026Randomized Controlled Trial
Impact of Time of Injection on the Efficacy and Safety of iGlarLixi Versus IDegAsp in Chinese People With Type 2 Diabetes: Exploratory Analysis of the Soli-D StudyLi X et al.Diabetes, obesity & metabolism2026Randomized Controlled Trial
Does faster aspart improve time in range in children with type 1 diabetes with glycaemia close to target on insulin pump therapy?Emilia KK et al.Diabetic medicine : a journal of the British Diabetic Association2026Randomized Controlled Trial
Comparison of pharmacodynamics and pharmacokinetics of ultra-rapid-acting insulin aspart and rapid-acting insulin aspart around continuous moderate intensity exercise in adults with type 1 diabetes: A randomised controlled trialPitt JP et al.Diabetes, obesity & metabolism2026Randomized Controlled Trial
Efficacy and safety of insulin degludec/insulin aspart biosimilar B01711 vs originator insulin degludec/insulin aspart in Chinese patients with type 2 diabetes inadequately controlled on basal or premixed insulin: A multicenter, randomized, open-label, phase 3 studyGao L et al.Journal of diabetes investigation2026Randomized Controlled Trial
Efficacy and safety of iGlarLixi versus IDegAsp by baseline β-cell function in Chinese people with type 2 diabetes: Exploratory analyses of the Soli-D studyGu W et al.Diabetes, obesity & metabolism2026Randomized Controlled Trial
Glycemic Benefit of Insulin Degludec/Insulin Aspart Compared to Basal Insulin in Type 2 Diabetes Mellitus Associated with Impaired Glucagon-Like Peptide-1 Response: A Randomized Crossover TrialJang HN et al.Diabetes & metabolism journal2026Randomized Controlled Trial
Impact of Ultra-Rapid Insulin on Boost and Ease-Off in the Cambridge Hybrid Closed-Loop System for Individuals With Type 1 DiabetesRoyston C et al.Journal of diabetes science and technology2026Randomized Controlled Trial
A Pilot Outpatient Assessment of a Fully Closed-Loop Insulin and Pramlintide SystemOdabassian M et al.Journal of diabetes science and technology2025Randomized Controlled Trial
Assessing biosimilarity of insulin aspart injection and NovoRapid® through pharmacokinetic and pharmacodynamic comparisons in healthy volunteers: A double-blind, randomized, crossover studySanthanam R et al.European journal of pharmacology2025Randomized Controlled Trial
Fully Closed-Loop Improves Glycemic Control Compared with Pump with CGM in Adolescents with Type 1 Diabetes and HbA1c Above Target: A Two-Center, Randomized Crossover StudyKadiyala N et al.Diabetes technology & therapeutics2025Randomized Controlled Trial
Insulin degludec/insulin aspart (IDegAsp) treatment on glycemic control and weight in patients with insulin experienced uncontrolled type 2 diabetes mellitus: A retrospective observational studyCakmak R et al.Endocrine regulations2025Observational Study
Evaluation of Pharmacokinetics and Safety of the Biosimilar (B01711) and Insulin Degludec/Insulin Aspart (IDegAsp, Ryzodeg) in Healthy Chinese Adults in a Randomized, Open-Label, Single-Dose, Crossover, Phase I StudyLiu H et al.Drug design, development and therapy2025Randomized Controlled Trial
An open-label, multiple ascending dose trial of orally administered insulin Tregopil in patients with type 1 diabetes mellitus to evaluate its pharmacokinetics, pharmacodynamics, safety and tolerabilityLatres E et al.Diabetes, obesity & metabolism2025Clinical Trial, Phase I
Faster-acting insulin aspart versus insulin aspart for adults with type 1 diabetes treated with non-automated insulin pump and continuous glucose monitoring-A double-blind randomized controlled crossover trialRanjan AG et al.Diabetes, obesity & metabolism2025Randomized Controlled Trial
Impact of Meal Insulin Bolus Timing and Bedtime Snacking on Continuous Glucose Monitoring-Derived Glycemic Metrics in Hospitalized InpatientsAlexanian SM et al.Diabetes technology & therapeutics2025Randomized Controlled Trial
Effect of insulin aspart combined with insulin detemir and metformin on islet function in newly diagnosed type 2 diabetes mellitusWang H et al.Journal of drug targeting2025Randomized Controlled Trial
Postprandial time in tight range with faster insulin aspart compared with standard insulin aspart in youth with type 1 diabetes using automated insulin deliveryDovč K et al.Diabetes, obesity & metabolism2025Randomized Controlled Trial
Equivalence of Biosimilarity in Pharmacokinetic and Pharmacodynamic Properties of Recombinant Human Insulin AspartDongre SA et al.Clinical pharmacology in drug development2025Randomized Controlled Trial
Comparing Postprandial Glycemic Control Using Fiasp vs Insulin Aspart in Hospitalized Patients With Type 2 DiabetesAlexanian SM et al.Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists2025Randomized Controlled Trial
Sensor-derived glycaemic metrics in pregnant women with type 1 diabetes randomised to faster acting insulin aspart or insulin aspart-A secondary analysis of the CopenFast trialSøholm JC et al.Diabetic medicine : a journal of the British Diabetic Association2025Randomized Controlled Trial
Safety and Efficacy of Switching SAR341402 Insulin Aspart and Originator Insulin Aspart vs Continuous Use of Originator Insulin Aspart in Adults With Type 1 Diabetes: The GEMELLI X TrialShah VN et al.Journal of diabetes science and technology2025Randomized Controlled Trial
Effect of Postmeal Fast-Acting Insulin Aspart Injection on the Frequency of Hypoglycemia among Pre-School Children with Type 1 Diabetes: An Open-Label, Cross-Over, Randomized Control TrialYadav A et al.Indian journal of pediatrics2025Randomized Controlled Trial
Survey of fear and compliance of Insulin Degludec and Insulin Aspart injection in type 2 diabetes mellitus patients and analysis of influencing factorsXie M et al.Medicine2024Observational Study
Assessing the influence of insulin type (ultra-rapid vs rapid insulin) and exercise timing on postprandial exercise-induced hypoglycaemia risk in individuals with type 1 diabetes: a randomised controlled trialMolveau J et al.Diabetologia2024Randomized Controlled Trial
The efficacy and safety of iGlarLixi versus IDegAsp in Chinese people with type 2 diabetes suboptimally controlled with oral antidiabetic drugs: The Soli-D randomized controlled trialLiu M et al.Diabetes, obesity & metabolism2024Randomized Controlled Trial
Simple meal announcements and pramlintide delivery versus carbohydrate counting in type 1 diabetes with automated fast-acting insulin aspart delivery: a randomised crossover trial in Montreal, CanadaCohen E et al.The Lancet. Digital health2024Randomized Controlled Trial
Effect of needle-free injection on psychological insulin resistance and insulin dosage in patients with type 2 diabetesWang W et al.Frontiers in endocrinology2024Randomized Controlled Trial

More cited research

Conditions researched

Related compounds

FAQ

What is Insulin Aspart?

A rapid-acting mealtime insulin analog; brands include NovoLog, NovoRapid and Fiasp.

How many registered human trials study Insulin Aspart?

The PeptideWhiz trial index lists 488 registered trials for Insulin Aspart, the most recent from 2026.

How much published research exists on Insulin Aspart?

The PeptideWhiz paper index links 450 PubMed papers to Insulin Aspart; by study type, 513 human and 0 animal studies.

Which conditions is Insulin Aspart researched for?

Atherosclerosis, cardiovascular disease & high blood pressure, Chronic and systemic inflammation, Concussion, traumatic brain injury & stroke recovery, Delayed gastric emptying on GLP-1 medicines, Dementia, Alzheimer's & cognitive decline, Fat loss, obesity & body recomposition, Fatty liver & elevated liver enzymes, Heart repair: after heart attack, heart failure & enlarged heart, High cholesterol and statins, Insulin resistance, prediabetes & type 2 diabetes, Kidney protection (CKD, diabetic kidney, lupus kidney), Low blood pressure and orthostatic hypotension, Lung health, asthma & COPD, Neuropathy and CRPS, Post-surgical inflammation and surgery recovery, Pregnancy and breastfeeding: safety notes, Skin, hair loss, wounds & mast-cell/histamine reactivity.

Research and education only. Not medical advice. No dosing guidance. Data: ClinicalTrials.gov registry and PubMed via the PeptideWhiz index (204,289 studies).